Sec Form 4 Filing - Raday Gilead @ RedHill Biopharma Ltd. - 2026-04-06

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Raday Gilead 2. Issuer Name and Ticker or Trading Symbol RedHill Biopharma Ltd. [ RDHL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) 21 HA'ARBA'A STREET 3. Date of Earliest Transaction (MM/DD/YY) 04/06/2026 (Street) TEL AVIV6473921 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 04/06/2026 S( 1 ) 15,740,000 ( 1 ) D $ 0.0001 ( 2 ) 261,060,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares American Depositary Shares ( 3 ) 04/06/2026 M 30,780,000 ( 3 ) ( 3 ) Ordinary Shares 30,780,000 $ 0 76,150,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Raday Gilead 21 HA'ARBA'A STREET TEL AVIV6473921 Chief Operating Officer Signatures /s/ Gilead Raday 04/22/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The reporting person sold 1,574 American Depositary Shares ("ADS") of RedHill Biopharma Inc. (the "Issuer"), each ADS represents 10,000 ordinary shares, par value NIS 0.01 per share, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,652 restricted share units granted to him on July 1, 2023, June 24, 2024, March 26, 2025 and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person. ( 2 )The price reported in Table I Column 4 is $0.8001 per ADS, which would be equivalent to $0.00008001 per ordinary share. ( 3 )Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.